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In vitro susceptibility of 58 isolates of Pichia anomala to five antifungal drugs using two broth microdilution
methods (CLSI and EUCAST) was analyzed. Low susceptibility to itraconazole was observed. Fluconazole,
voriconazole, amphotericin B, and caspofungin showed good antifungal activity, although relatively high drug
concentrations were necessary to inhibit the isolates.
Several reports have pointed to Pichia anomala (anamorph
Candida pelliculosa) as a cause of a large spectrum of invasive
infections (13, 20, 23, 35), fungemia being the most common
presentation (2, 6, 17, 26, 41). Usually, the patients have been
treated with amphotericin B (with or without 5-flucytosine) or
fluconazole with good clinical outcomes (3, 6, 12, 16, 26, 38).
Nonetheless, treatment failures may occur (1, 6, 43), as may
cases of breakthrough fungemias in immunocompromised pa-
tients receiving prophylaxis with fluconazole (14).
Although P. anomala is considered an emergent hematoge-
nous yeast pathogen, data on the susceptibility of P. anomala
to antifungal drugs are scarce (4, 5, 19, 29, 33). The aim of this
study was to determine the in vitro susceptibility profile to five
antifungal drugs of a large collection of P. anomala isolates
from blood cultures of patients with nosocomial fungemia.
For this purpose, 52 nonrelated bloodstream isolates of P.
anomala (36 from Brazil, 13 from Argentina, and 3 from
Spain) and 6 from unknown clinical specimens (United States)
were tested by two broth microdilution methods, those of the
Clinical and Laboratory Standards Institute (CLSI; formerly
NCCLS) (21) and the European Committee on Antibiotic Sus-
ceptibility Testing (EUCAST) (37) guidelines.
We evaluated the activity of amphotericin B (Sigma), itra-
conazole (Janssen Pharmaceutica), voriconazole (Pfizer, Inc.),
and caspofungin (Merck & Co.) at concentrations ranging
from 0.015 to 8 g/ml and of fluconazole (Pfizer, Inc.) at
concentrations ranging from 0.12 to 64 g/ml.
The inhibition criterion adopted to determine the MIC for
amphotericin B was the lowest drug concentration which pro-
duced complete or nearly complete (95%) inhibition com-
pared with the drug-free control well (25). For azoles (21) and
caspofungin (24), the lowest concentration which produced
50% inhibition was used.
All MICs were determined spectrophotometrically (530 nm)
after incubation for 24 h (EUCAST) or 48 h (CLSI). To cat-
egorize the isolates as susceptible, we employed the CLSI (21)
interpretive criteria for fluconazole (8 g/ml) and itracon-
azole (0.12 g/ml); for voriconazole, we used a recently es-
tablished breakpoint (BP) of 1 g/ml (30). Based on phar-
macokinetic data, a BP of 1 g/ml was assumed for
caspofungin (40) and for amphotericin B (22, 29). The CLSI
interpretive criteria were also adopted for EUCAST results for
comparison only, as EUCAST BPs have not been defined yet.
In our study, we found an excellent agreement (2-fold
dilutions) between MIC results generated by the EUCAST and
CLSI methods for all antifungal drugs (Table 1). The lowest
agreement rate was observed for itraconazole assays, as re-
ported in a previous study testing other Candida species (10).
In evaluations of the differences among MICs obtained by the
two methods, EUCAST produced statistically significant lower
MICs for voriconazole, amphotericin B, and caspofungin (Ta-
ble 1). However, despite these differences, all isolates were
categorized as susceptible by both methods, according to the
assumed BPs. Although both methods were suitable to test P.
anomala, the 24 h of incubation with the EUCAST method
provided a clear spectrophotometric endpoint reading, which
represents an advantage by reducing the incubation time.
No remarkable differences were observed when the geo-
graphic distribution of the isolates was considered (data not
shown), and so Table 2 presents in a continuous fashion the
cumulative percentages of all 58 P. anomala isolates that were
found to be susceptible at each dilution throughout the serial
dilutions. We could observe that MICs tended to concentrate
* Corresponding author. Mailing address: Instituto Adolfo Lutz, Av
Dr. Arnaldo 351, 11° andar, Sa˜o Paulo, Sa˜o Paulo, Brazil 01246-901.
Phone: 55 11 3068 2900. Fax: 55 11 3085 3505. E-mail: mattav@usp.br.
 Published ahead of print on 29 January 2007.
1573
from the middle to the high end of the range for all the drugs.
Although almost all isolates were categorized as being suscep-
tible to fluconazole (Table 2), similar to results from other
investigators (19, 29, 33, 42), some studies showed different
results (5, 36). Indeed, the modal values, MIC50 and MIC90, of
our collection were close to those reported for C. glabrata (8,
9, 11, 27, 28, 34), a species of Candida that is considered to be
less susceptible to azoles than Candida albicans.
Itraconazole was the triazole with the lowest in vitro activity
against P. anomala, as more than 60% of all isolates showed
reduced sensitivity to the drug (Table 2). Also, the MIC50 and
MIC90 for itraconazole were much higher than those fre-
quently obtained for C. albicans (8, 11, 25, 34) and were similar
to those determined for Candida glabrata, Candida krusei, and
Candida guilliermondii (4, 10, 11, 18, 25, 34).
Voriconazole was very active against all P. anomala isolates
(Table 2), but MICs were usually higher than those reported
for C. albicans, Candida parapsilosis, and Candida tropicalis (7,
18, 28, 29, 31, 33). Actually, they were similar to MIC results
obtained by other investigators testing C. glabrata and C. krusei
(7, 18, 28, 29, 31).
In our study, amphotericin B MICs were tightly clustered
between 0.12 and 1.0 g/ml, and all isolates were considered
susceptible to the drug (Table 2). In fact, the resistance of
Candida species to amphotericin B is a rare phenomenon that
may be associated with the low sensitivity of broth microdilu-
tion methods in identifying resistant strains.
Caspofungin presented good in vitro activity against P.
anomala, as all isolates were inhibited by 1 g/ml (Table 2).
However, their MICs were higher than those usually necessary
to inhibit most isolates of C. albicans, C. tropicalis, and C.
glabrata. (7, 15, 25, 32). The only other study on the suscepti-
bility of P. anomala to caspofungin generated MIC50 values
eight times lower than those in our report. This finding may be
explained partially by differences in the incubation times used
in the two studies, as we read the CLSI MICs at 48 h instead
of 24 h as suggested by Pfaller et al. (32). In fact, we were not
able to determine MICs with confidence at 24 h by using the
CLSI inoculum, in contrast with the 100-fold-higher EUCAST
inoculum. Finally, neither trailing nor paradoxical growth was
seen in our series of P. anomala isolates with caspofungin, as
observed for some Candida species (25, 39).
In summary, P. anomala did not show intrinsic resistance to
any of the drugs studied. Nonetheless, susceptibility to itracon-
azole was poor. In contrast, fluconazole, voriconazole, ampho-
tericin B, and caspofungin presented good activity against P.
anomala, although relatively high drug concentrations were
necessary to inhibit the isolates. Altogether, the susceptibility
TABLE 1. Distribution of P. anomala isolates according to differences in MIC results obtained by the EUCAST and CLSI methods
Antifungal drug
No. of iolates for which EUCAST MICs differed
from CLSI MICs by indicated no. of dilutionsa
Agreement
within
indicated no.
of dilutions
(%)
Mean difference
(log2 values)
95% Confidence interval
3 2 1 0 1 2 3 1 2
Fluconazole 6 8 33 9 2 86 100 0.12 0.36 to 0.12
Itraconazole 1 2 14 30 10 1 93 96 0.14 0.38 to 0.11
Voriconazole 3 23 28 4 95 100 0.43 0.62 to 0.25
Amphotericin B 1 22 27 8 98 100 0.28 0.46 to 0.90
Caspofungin 8 32 16 2 86 100 0.80 0.98 to 0.60
a Fifty-eight P. anomala isolates were tested with each drug.
TABLE 2. Antifungal drug susceptibility profile of P. anomala determined by CLSI and EUCAST broth dilution methods
Antifungal drug and
microdilution method
Cumulative % of susceptible isolatesa at MIC (g/ml) of:
Mode Geometricmean, MIC
%
Susceptibilityb0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16
Fluconazole
CLSI 0 0 0 0 0 0 0 15.5 56.8 93 100 4 5.08 96.6
EUCAST 0 0 0 0 0 0 0 22.4 55.1 96.5 100 8 4.79 93
Itraconazole
CLSI 1.7 0 12 36.1 74.1 96.5 100 0.25 0.21 36.2
EUCAST 0 0 7 39.5 91.2 98.2 100 0.25 0.19 39.6
Voriconazole
CLSI 0 3.4 18.9 39.6 96.5 100 0.25 0.16 100
EUCAST 0 3.4 29.3 65.5 100 0.12 0.12 100
Amphotericin B
CLSI 0 0 0 12 36 88 100 0.5 0.45 100
EUCAST 0 0 0 15.5 55.1 94.7 100 0.25 0.37 100
Caspofungin
CLSI 0 1.7 17.2 84.5 100 0.12 0.12 100
EUCAST 0 12 70.6 100 0.06 0.07 100
a n  58.
b EUCAST and CLSI MICs were interpreted according to CLSI breakponts for fluconazole and itraconazole. For voriconazole, amphotericin B, and caspofungin,
the adopted breakpoint was 1 g/ml.
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profile of P. anomala was more similar to that of C. glabrata
than to that of C. albicans. Trailing and paradoxical growth
were not observed in the presence of any antifungal drug
tested.
Finally, our study analyzed the largest series studied to date
of P. anomala bloodstream isolates tested against five antifun-
gal drugs by two different methods and could establish a reli-
able susceptibility profile for P. anomala, as an attempt to
guide the choice of antifungal drugs for therapy in cases of
invasive infections.
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